DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBV Technologies (DBVT) will participate in two November investor conferences, with a fireside chat and one-on-one investor meetings scheduled. The Guggenheim Securities 3rd Annual Healthcare Innovation Conference fireside chat takes place on November 9, 2026, at 8:00 am ET in Boston. The company will hold one-on-one meetings at the 2026 LifeSci Growth & Innovation Summit on November 16, 2026 in London.
A live webcast of the fireside chat will be available through the Events section of the company’s website, with a replay available for 90 days after the event.
DBV Technologies (DBVT) reported a third-quarter net loss of $64.5 million while advancing its VIASKIN Peanut Patch regulatory application. The loss widened from $33.2 million a year earlier. Cash and cash equivalents were $165.7 million at September 30, 2026; DBV estimates funding into the third quarter of 2027, but disclosed substantial doubt about its ability to continue as a going concern.
The company submitted its U.S. marketing application for children aged 4 through 7 on September 29, 2026, requesting Priority Review. FDA's filing-acceptance and Priority Review decisions are expected in the fourth quarter of 2026. DBV expects to submit its application for toddlers aged 1 through 3 in 2027. It also completed a $50 million gross ADS sale to RA Capital Management and refreshed its $150 million at-the-market share-sale program. Commercial preparations continued for a potential launch, subject to approval.
DBV Technologies (DBVT) will report third-quarter 2026 financial results and provide a business update on October 28, 2026.
The company will host an investor conference call and live audio webcast at 5:00 p.m. ET that day to review the results. The webcast will be available through the Events section of the company’s website.
DBV Technologies (DBVT) has submitted a U.S. FDA approval application for the VIASKIN Peanut Patch in children aged 4–7 with peanut allergy. The submission is a Biologics License Application, the request for permission to market a biological treatment. DBV has requested Priority Review; the FDA previously granted the patch Breakthrough Therapy Designation.
The application is supported by Phase 3 VITESSE results that DBV describes as positive. The trial enrolled 654 children, randomly assigned 2:1 to the patch or placebo, across 86 sites. It evaluated the efficacy and safety of the 250 µg patch using a double-blind design, with participants and investigators unaware of treatment assignments. Its primary endpoint compares the percentage of treatment responders in the active and placebo groups after 12 months.
DBV Technologies (DBVT) will participate in three investor conferences in New York in September 2026, including the Cantor Global Healthcare Conference on September 9, Citi’s Biopharma Back to School Conference on September 10, and the H.C. Wainwright Global Investment Conference on September 15.
The company will host fireside chats at the Cantor and H.C. Wainwright events, at 1:00 p.m. ET and 3:00 p.m. ET respectively, with live webcasts available on its website for 90 days. DBV Technologies is a late-stage biopharmaceutical company developing epicutaneous immunotherapy (EPIT) using its VIASKIN® Peanut Patch for toddlers and children with peanut allergy.
DBV Technologies (DBVT) reported its capital and voting rights as of August 31, 2026 in accordance with Article 223-16 of the AMF General Regulations. The company had 314,388,807 shares outstanding, with a total gross voting rights count of 314,388,807 and a total net voting rights count of 314,222,095.
DBV Technologies (Nasdaq: DBVT) has agreed to sell approximately $50 million of American Depositary Shares (ADSs) under its At-The-Market (ATM) program on Nasdaq to RA Capital Management, through Citizens JMP Securities as sales agent. Each ADS represents five new ordinary shares.
The company will issue 18,288,220 new ordinary shares (3,657,644 ADSs) at $13.67 per ADS, equivalent to €2.3824 per ordinary share, a 0.15% discount to the last Euronext Paris closing price of €2.39. Settlement and delivery are expected on August 3, 2026.
The new shares will represent 6.18% of existing Euronext Paris-listed shares and imply approximately 5.82% dilution for current shareholders. Post‑transaction, total shares increase from 296,087,162 to 314,375,382, with RA Capital holding 18,288,220 shares (5.82% of capital).
DBV Technologies (Nasdaq: DBVT, Euronext: DBV) has filed an automatically effective shelf registration statement on Form S-3ASR with the SEC, including a base prospectus and a sales agreement prospectus supplement, to refresh its existing at-the-market offering program for up to $150 million of American Depositary Shares (ADSs).
The ATM program, conducted under a September 5, 2025 sales agreement with Citizens JMP Securities acting as sales agent, keeps total capacity at $150 million by carrying forward previously registered but unsold ADSs and adding newly registered capacity. Each ADS represents five ordinary shares, and issuances are subject to French regulatory limits, including a Prospective Regulation exemption for offerings to qualified investors representing less than 30% of securities already admitted over 12 months. DBV intends to use any net proceeds mainly for manufacturing expansion, BLA activities in ages 1–3 and 4–7, potential launch preparation of Viaskin Peanut in ages 4–7 if approved, product development, and general corporate purposes.
DBV Technologies (Nasdaq: DBVT) announced that it has filed its 2026 Half-Year Report for the semester ended June 30, 2026 with the French market authority, Autorité des Marchés Financiers (AMF). According to the company, the report is available in French on its website under Investors/Financial Information and on the AMF website.
DBV Technologies (Nasdaq: DBVT) reported second quarter and half-year 2026 results, highlighting continued regulatory progress for the VIASKIN® Peanut Patch in children aged 4–7 years. The company is engaged in detailed, ongoing interactions with the FDA and now anticipates submitting its BLA in the third quarter of 2026, with no additional data requested to date.
DBV closed enrollment in the COMFORT Toddlers safety study, initiated the THRIVE study in infants, and remains funded into the third quarter of 2027, supported by $174.9 million in cash and cash equivalents at June 30, 2026. For the first half of 2026, operating income was $1.6 million, operating expenses $100.1 million, and net loss $98.0 million, or $(0.23) per share, compared with a $(0.58) loss per share a year earlier. Net cash used in operating and investing activities rose to $102.6 million, reflecting increased clinical, manufacturing, and commercial readiness investments.